Pneumococcal conjugate second or third-dose vaccines (PCVc) in Andorra
Andorra: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 93.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Andorra, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Andorra is 93.0%, measured in 2025.
Compared with earlier readings it is down 3.1% on the previous year and up 1.1% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Andorra peaked at 98.0% in 2017 and was at its lowest, 0.0%, in 2008.
Andorra ranks 53rd of 194 countries on this measure, in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Andorra, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 93.0% | — |
| 2015 | 92.0% | -1.1% |
| 2016 | 92.0% | +0.0% |
| 2017 | 98.0% | +6.5% |
| 2018 | 94.0% | -4.1% |
| 2019 | 96.0% | +2.1% |
| 2020 | 96.0% | +0.0% |
| 2021 | 95.0% | -1.0% |
| 2022 | 95.0% | +0.0% |
| 2023 | 94.0% | -1.1% |
| 2024 | 96.0% | +2.1% |
| 2025 | 93.0% | -3.1% |
Andorra compared with similar countries
- Andorra's 93.0% is above the median for high income countries, which is 91.0%, 1.0× the median. (63 countries reporting)
- Andorra's 93.0% is above the median for Europe & Central Asia, which is 87.0%, 1.1× the median. (51 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 56.5% | 0.0% | 98.0% | 10 |
| 2020s | 94.8% | 93.0% | 96.0% | 6 |
Countries ranked near Andorra
More health data for Andorra
- Number of infants who die before age 1 0 deaths (2100)
- Estimated changes in temperature-related death rates compared to projected death rates 1,824 deaths per 1,000 people (2090)
- Heat deaths vs projected death rates, annual growth rate 0.0878 % change on previous year (2090)
- Un projection of annual infant deaths, annual growth rate -100 % change on previous year (2077)
- Population, male, per capita 0.511 units per person (2025)
- Deaths in armed conflicts by region 0 deaths (2026)
- Deaths in armed conflicts based on where they occurred 0 deaths (2026)
- Population, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population, male, annual growth rate 1.14 % change on previous year (2025)
- Population ages 00-04, female, annual growth rate 6.28 % change on previous year (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Andorra?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Andorra was 93.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Andorra?
- The highest recorded value was 98.0% in 2017.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Andorra?
- The lowest recorded value was 0.0% in 2008.
- How does Andorra rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Andorra ranks 53rd out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Andorra?
- Over the last ten years it is up 1.1%. The long-run trend across the full record is volatile.
- Where does this Andorra data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).